Paper Details

  1. Home
  2. Paper Details

SC-36602, a new antiarrhythmic agent: comparison of its cardiovascular profile with that of other antiarrhythmic drugs.

Author: FrederickL G, GarthwaiteS M, HatleyF R, McDonaldS J, StammM H

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

SC-36602, a new class 1A/1B antiarrhythmic agent, was found to have fewer hemodynamic side effects than other antiarrhythmic agents at its antiarrhythmic dose in dogs. SC-36602 did not cause significant myocardial depression and had the least direct negative inotropic action of the drugs studied.
Paper Details　
Original Abstract of the Article :
The cardiovascular profile of SC-36602, a new class 1A/1B antiarrhythmic agent, was compared to those of disopyramide, lidocaine, mexiletine, flecainide, encainide, lorcainide, and quinidine. These drugs were compared at their respective canine antiarrhythmic doses in a hemodynamic evaluation using ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/2457760

データ提供：米国国立医学図書館（NLM）

SC-36602: A New Antiarrhythmic Agent

This research examines the cardiovascular profile of [SC-36602], a new antiarrhythmic agent, and compares it to the profiles of other antiarrhythmic drugs. It’s like comparing the effects of different types of desert herbs on a camel's heart, seeking the most effective and safe solution for irregular heartbeats.

Cardiovascular Profile Comparison

The study compares the hemodynamic effects of SC-36602 to those of disopyramide, lidocaine, mexiletine, flecainide, encainide, lorcainide, and quinidine, assessing their impact on heart rate, blood pressure, and ECG intervals. The authors found that SC-36602 had a favorable cardiovascular profile with minimal hemodynamic side effects.

Potential for a Safer Antiarrhythmic Treatment

This research suggests that SC-36602 may be a safer and more effective option for treating arrhythmias compared to some existing antiarrhythmic drugs. However, further research is needed to confirm its long-term safety and efficacy.

Dr.Camel's Conclusion

This research offers a promising new oasis in the desert of arrhythmia treatment. By understanding the unique cardiovascular profile of SC-36602, we can explore its potential as a safer and more effective antiarrhythmic agent, providing hope for a healthier heart rhythm.

Date :
  1. Date Completed 1988-09-26
  2. Date Revised 2014-11-20
Further Info :

Pubmed ID

2457760

DOI: Digital Object Identifier

2457760

Related Literature

Article Analysis
・Side Effects of disopyramide
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.